Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects aged between 35 and 70 years, inclusive~* type 2 diabetes with duration \>6 months and \<10 years~* for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas~* HbA1c \>=7.0% and \<=10.0%~* if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start~* written informed consent~Exclusion Criteria:~* history or presence of cancer or any clinically relevant diseases~* chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months~* recurrent hypoglycemia~* abnormal lab tests at screening (ALAT and/or ASAT \>=3 times ULN), creatinine \>1.6 mg/dL in males and \>1.4 mg/dL in females~* clinically relevant ECG findings at screening~* treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months~* treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months~* any systemic or topical treatment with drugs known to influence glucose metabolism

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- insulin glargine + exenatide + metformin (Type: EXPERIMENTAL): None
- Insulin glargine + sitagliptin + metformin (Type: EXPERIMENTAL): None
- insulin glargine + metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).